Advertisement

Related Videos

Welcome and Introduction to Vi3C

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Advertisement

Advertisement




Oct
13
Today In Oncology
Gaps Persist in Follow-Up Care Among Young Survivors of Breast Cancer
Ziftomenib in Relapsed or Refractory NPM1-Mutant AML
Advanced Biliary Tract Cancer Adding a Polymeric Micellar Paclitaxel to Gemcitabine Plus Cisplatin
Incidence of Invasive Lobular Carcinoma Rising Faster Than Other Breast Cancers
Prior Authorization Is Burdensome for Patients, Resulting in Treatment Delays, Financial Strain, and Stress
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo